About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNCT04009421

Coronary Artery Plaque Burden in Stable Angina and Non-obstructive Coronary Artery Disease

Non-obstructive coronary artery disease (CAD), particularly common in women, has been associated with impaired quality of life and risk of recurrent hospitalizations. Several studies have also demonst...

Lead sponsor: University of Bergen•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

University of Bergen

Collaborators

Haukeland University Hospital

Patients with stable angina and non-obstructive coronary artery disease by CT coronary angiography will be selected from the Norwegian Registry of Invasive Cardiology (NORIC). This is a national quality control registry run and controlled by the Norwegian Institute of Public Health (www.fhi.no). All CT coronary angiograms will be reanalyzed using advanced post-processing analysis software to assess coronary artery plaque burden, distribution and composition. Through linking with the Norwegian Cardiovascular Disease Registry and the Cause of Death Registry (www.fhi.no) we will be able to assess the association between long-term prognosis (5 years) and coronary artery plaque features.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Stable angina
•Non-obstructive coronary artery disease by CT coronary angiography defined as \<50% stenosis (lumen diameter reduction)

Exclusion Criteria

•Obstructive coronary artery disease
•Unstable angina
•Previous myocardial infarction, heart surgery or percutaneous coronary interventions

Related studies

Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

NCT07329699 · Coronary Artery Disease, Chronic Coronary Syndrome, and more

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

NCT06863155 · Coronary Artery Disease, Ischemic Heart Disease

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT06779630 · Coronary Artery Disease

TIMELY-PrädiktoR Prospective Study

NCT05461729 · Coronary Artery Disease

RECRUITINGPhase 1/2

A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease

NCT07493603 · Coronary Heart Disease, Coronary Artery Disease, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 29, 2023Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment1,400

Start dateFeb 2018

Last updatedNov 29, 2023

Condition

Coronary Artery Disease Plaque, Atherosclerotic

Locations shown

Department of Clinical Science, University of Bergen

Bergen

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 29, 2023Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions